FKBP8/38 agonists can reduce fat-induced hyperlipidemia [66], with hyperlipidemia being a key feature of dysferlinopathy in LGMD2B/LGMDR2. This evidence concerns the gene DYSF and neuromuscular disease caused by qualitative or quantitative defects of dysferlin.